Dr. Sabine Straus

Dr. Sabine Straus has been with the Medicines Evaluation Board (MEB) in the
Netherlands since 1997, where she started as an assessor Pharmacovigilance.
Prior to working at the MEB she held different positions in the pharmaceutical
industry, the last one as medical director.
In the period 2001-2005 she combined her work at the MEB with a research
position at the Erasmus Medical Center in Rotterdam on the topic “drugs, Qtc
prolongation and sudden cardiac death” that resulted in a PhD degree. During
this period she completed her Master of Science in Clinical Epidemiology.
In the period 2005-2012 she is has been head of the Pharmacovigilance
department (2005-2012) and member of the PharmacoVigilance Working Party
(PhVWP).
Since the start of the Pharmacovigilance Risk Assessment Committee (PRAC) in
2012 she has been the Dutch member and staff member at the MEB.
In that period she co-chaired the Signal Management Review Team (SMaRT),
and has been active in several drafting groups for guidance and guidelines.
Since 2018 she chairs the PRAC.
In addition to her work at the MEB she holds a position as associate professor at
the Erasmus Medical Center, department of Medical Informatics in Rotterdam.